Clinical phase 3 study to monitor the safety, tolerability, and efficacy of subcutaneous human immunoglobulin (cutaquig ®) administered at modified dosing regimens in patients with primary immunodeficiency diseases

Condition:   Primary Immune Deficiency Disorder Intervention:   Drug: CUTAQUIG Sponsor:   Octapharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials